



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting
November 28, 2018**

NOTE: Unless the information is confidential, the reports, presentations, and grant award information referenced in the minutes are available at <http://ocmeetings.cprit.texas.gov> in the "Meeting Packet" section for the corresponding meeting date.

Call to Order – Agenda Item 1

A quorum being present, Presiding Officer Will Montgomery called the Oversight Committee to order at 10:02 a.m.

Oath of Office for David A. Cummings, M.D. – Agenda Item 3

Presiding Officer Montgomery administered the oath of office to Dr. Cummings. Governor Greg Abbott appointed Dr. Cummings to the Oversight Committee for a term expiring January 31, 2023.

Roll Call/Excused Absences – Agenda Item 2

Committee Members Present

Bill Rice, M.D.
Craig Rosenfeld, M.D.
Will Montgomery
Mahendra Patel, M.D.
David Cummings, M.D.

Committee Members Absent

Donald (Dee) Margo
Angelos Angelou

MOTION:

On a motion by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the excused absences of Mr. Margo and Mr. Angelou.

Adoption of Minutes from the August 24, 2018 Meeting – Agenda Item 4 – Tab 1

MOTION:

On a motion by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meeting of August 24, 2018, as presented.

Public Comment – Agenda Item 5

There were no requests to provide public comment.

Grantee Presentation – Agenda Item 6 – Tab 2

Dr. Willson introduced CPRIT grantee, Livia Eberlin, Ph.D., assistant professor in the Department of Chemistry at the University of Texas at Austin.

Dr. Eberlin provided an overview of the development of the MasSpec Pen and its potential as a tool for real time cancer diagnostics. She discussed her CPRIT-funded research that supports collaborations between her program at UT Austin and surgeons at MD Anderson and Baylor College of Medicine to evaluate the MasSpec Pen for diagnosis of thyroid (RP170427), lung (RP160776), and ovarian (RP180381) cancers. Dr. Eberlin acknowledged the opportunities that her CPRIT funding has enabled and the unique translational research resources in Texas that has accelerated her research forward.

Dr. Eberlin's presentation was enthusiastically received and led to several questions by the Oversight Committee members regarding the mass spectroscopy technology and potential application beyond those cancers discussed.

Presiding Officer Montgomery recognized Dr. Eberlin for her recent 2018 MacArthur Foundation Fellowship. Presiding Officer Montgomery also noted that Dr. Jim Allison of UT MD Anderson Cancer Center received the 2018 Nobel Prize in Medicine and Dr. Zhijian "James" Chen of UT Southwestern received the 2019 Breakthrough Prize.

Chief Executive Officer Report – Agenda Item 7 – Tab 3

Presiding Officer Montgomery recognized Mr. Roberts for the CEO report.

Mr. Roberts reported that the interviews for a new Chief Product Development Officer would begin the following week and that CPRIT should fill the position by late January.

He stated that the approval of today's award recommendations would leave more than \$260 million in grant award funds remaining for fiscal year 2019.

Mr. Roberts highlighted current legislation of interest to CPRIT, reporting that Representative Zerwas, a physician from Fort Bend County, pre-filed a bill to increase the bonding authority for CPRIT from \$3 billion to \$6 billion (HJR 12) as well as a second bill repealing the prohibition against CPRIT making new awards after August 31, 2022 (HB39). Mr. Roberts also reported that Senator Schwertner pre-filed a bill requiring CPRIT to develop a plan for self-sufficiency (SB200). He noted that Senator Schwertner's bill contains the same text from self-sufficiency bills he has filed in previous sessions. Mr. Roberts indicated that CPRIT has included discussion of self-sufficiency in its statutorily required annual report for the past two years.

He directed members to the Texas Cancer Momentum Report and other draft handouts relating to CPRIT's reauthorization, budget, and means of funding. The finalized documents will be sent to the members electronically.

Mr. Roberts concluded his report noting that he and other CPRIT staff traveled to 15 events around the state in the past two months. The American Cancer Society Cancer Action Network (ACS CAN)

and Texas Healthcare and Bioscience Institute hosted most of the events. He noted that Cam Scott with (ACS CAN) has taken another job out of state, but that James Gray would take his place on an interim basis.

Chief Compliance Officer Report – Agenda Item 8 – Tab 4

Presiding Officer Montgomery recognized Vince Burgess, Chief Compliance Officer. Mr. Burgess presented the Compliance Report for the past quarter's activities, noting that the number of delinquent reports in fiscal year 2018 showed a slight increase from fiscal year 2017, with an average of 18 reports per month. He reported that the increase is attributable to the change in Matching Compliance Certification (MCC) form reporting requirements in CGMS, as mentioned in previous meetings.

Mr. Burgess discussed the chart on page 4-4 of the meeting booklet showing data from the last four fiscal years.

A committee member asked Mr. Burgess if his team reached out to grantees with recurring issues. He confirmed that Compliance provides additional, targeted training to grantees on an as-needed basis.

Chief Scientific Officer Report – Agenda Item 9 – Tab 5

Presiding Officer Montgomery recognized CPRIT Chief Scientific Officer Dr. Jim Willson to present the academic research program update and the award slate recommended by the CPRIT Scientific Review Council (SRC) and the Program Integration Committee (PIC).

Dr. Willson referred the members to pages 5-1 and 5-2 of the meeting book describing the Request for Applications (RFA) planning and explained that, given the reduced funding available to CPRIT in Fiscal Years 2020 and 2021, CPRIT's Academic Research Program plans to reduce the number of annual grant cycles. Instead of two grant cycles per year, Academic Research will offer one application cycle in 2020 that will include the following grant mechanisms:

- Individual Investigator Research Awards (untargeted)
- Individual Investigator Research Awards for Cancer in Children and Adolescents
- Individual Investigator Research Awards for Prevention and Early Detection
- Individual Investigator Research Awards for Clinical Translation

CPRIT will continue to offer always-open Recruitment RFAs.

Responding to a committee member's question, Dr. Willson agreed that if the Legislature approves CPRIT's request for general revenue in the upcoming legislative session to maintain the amount available for grants at the same level as previous years, the academic research program will offer a second grant application cycle in Fiscal Year 2020.

In response to a committee member's inquiry regarding the practicality of issuing a Core Facility Support RFA in the final years of CPRITs award authority to support facility construction, Dr. Willson and Mr. Roberts noted that the core facility support awards do not fund construction of new facilities and explained that the award supports access to cutting-edge technology for cancer researchers.

Dr. Willson presented the Program Integration Committees grant award recommendations for Fiscal Year 2019 first quarter recruitment cycles 19.1, 19.2 and 19.3. The slate included two Established Investigators and two First-Time, Tenure Track Faculty Member nominations.

Rank	App ID	Candidate	Mechanism	Organization	Budget	Score
1	RR190003	Ansuman Satpathy, M.D., Ph.D.	RFTFM	Baylor College of Medicine	\$2,000,000	1.0
2	RR190017	Matthew Gubin, Ph.D.	RFTFM	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.5
3	RR190009	Thomas D. Wang, M.D., Ph.D.	REI	The University of Texas Southwestern Medical Center	\$6,000,000	1.8
4	RR190015	Shideng Bao, Ph.D.	REI	The University of Texas Health Science Center at San Antonio	\$6,000,000	2.0

Presiding Officer Montgomery noted that the outstanding scores of the candidates reflects on the ability of academic institutions to attract top candidates and the success of CPRITs Scholar's initiative.

Dr. Rice requested that Dr. Willson present data on the success rate of the recruitment to Texas of CPRIT Scholar applicants approved by the Scientific Review Council at the next Oversight Committee meeting in February 2019.

Compliance Certification

Mr. Burgess' presented the compliance certification report for the proposed academic research grant awards.

Conflict of Interest Notification

Presiding Officer Montgomery noted that no Oversight Committee member reported a conflict of interest with any applications under consideration.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Rosenfeld the Oversight Committee unanimously voted to approve the Program Integration Committee's recommendations for the Recruitment of Established Investigators and Recruitment of First-Time, Tenure-Track Faculty Members.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Rosenfeld the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to CPRIT's CEO and staff and authorized the CEO to sign the contracts on behalf of CPRIT.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Patel the Oversight Committee unanimously voted to approve the proposed fiscal year 2020 Cycle 1 Requests for Applications and timeline as recommended by Dr. Willson.

Chief Prevention and Communications Officer Report – Agenda Item 10 – Tab 7

Presiding Officer Montgomery recognized Chief Prevention and Communications Officer Dr. Becky Garcia to provide an update on the prevention program. Dr. Garcia gave a brief overview of the first cycle of grant applications for fiscal year 2019 and the RFAs CPRIT will issue for the second cycle.

Dr. Garcia responded to an Oversight Committee member's question regarding whether CPRIT funds therapeutic prevention studies, explaining that CPRIT's Academic Research program offers a funding mechanism, Individual Investigator Research Awards for Prevention and Early Detection, that supports applications addressing questions that will advance knowledge of the causes, prevention, progression, and/or early detection of cancer.

Communications Report

Dr. Garcia highlighted the soft launch of the new CPRIT website scheduled for November 30. She reported that staff will send a link to the members when the site is live. The site has a new design, new platform and retains the statutorily required content. In addition, it has new features such as an "Our Impact" section, digital newsroom, and new CPRIT Scholar section. She recognized the IT and Communications staff for their hard work.

Dr. Garcia also reported that the CPRIT Conference request for proposals received no responses so CPRIT will repost it with changes. She noted that the state hotel reimbursement rate is limiting some hotels' interest, but CPRIT is still looking at the summer of 2020 in surrounding cities. Dr. Rosenfeld suggested including hotels on South Padre Island.

Chief Product Development Officer Report – Agenda Item 11 – Tab 6

Presiding Officer Montgomery recognized Kristen Doyle, Interim Chief Product Development Research Officer, to present the Product Development Research Program update.

Ms. Doyle presented a brief update on Product Development Research Program and referred members to her memo included in the meeting packet at Tab 7. She noted that the Chief Product Development Officer will bring award recommendations for the first cycle of fiscal year 2019 to the Oversight Committee in February. She also reported that CPRIT will release three new Product Development Program requests for applications in early December. Ms. Doyle summarized the CPRIT Product Development program priorities for fiscal year 2020. The Product Development Research Program

did not propose any changes to the priorities that the Oversight Committee originally adopted for fiscal year 2019.

Mr. Roberts responded to an Oversight Committee member's question about the search process for the new Chief Product Development Officer, reviewing the steps taken in the search.

Presiding Officer Montgomery thanked Ms. Doyle for serving as Interim Chief Product Development Officer. Ms. Doyle recognized Rosemary French, Senior Program Manager for Product Development, for her assistance.

Scientific Research and Prevention Program Committee Appointments – Agenda Item 12 – Tab 8

Presiding Officer Montgomery recognized Mr. Roberts to present his 21 peer review appointments. Mr. Roberts noted that the Nominations Subcommittee discussed the appointments at its meeting on November 9 and recommended that the Oversight Committee vote to approve the appointments. He noted that CPRIT made bio sketches available electronically.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the Scientific Research Program Committee appointments.

Mr. Roberts informed the Oversight Committee of two new appointments to the University Advisory Committee: Dr. Claudia Neuhaser, Associate Vice Chancellor/Associate Vice President for Research and Technology Transfer at the University of Houston and Dr. Peter Davies, Head of the Institute of Biosciences and Technology and Professor at the Translational Cancer Center at Texas A&M University. Pursuant to CPRIT's statute, the chancellors of the various Texas institutions are responsible for appointing members to the University Advisory Committee and no Oversight Committee action was necessary.

Advisory Committee on Childhood Cancer Appointments – Agenda Item 13 – Tab 9

Presiding Officer Montgomery recognized Mr. Roberts to present the three proposed appointments to the Advisory Committee on Childhood Cancers. He reported that the Nominations subcommittee reviewed the Presiding Officer's appointments at the November 9 subcommittee meeting and recommended that the Oversight Committee vote to approve the appointments.

MOTION:

On a motion by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the three proposed appointments to the Advisory Committee on Childhood Cancer.

Fiscal Year 2020 Program Priorities - Agenda Item 14 – Tab 10

Presiding Officer Montgomery recognized Mr. Roberts to present the fiscal year 2020 Program Priorities for the Oversight Committee's consideration.

MOTION:

On a motion made by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the fiscal year 2020 program priorities.

Internal Auditor Report – Agenda Item 15 – Tab 11

Presiding Officer Montgomery recognized CPRIT’s internal auditor, Dan Graves with Weaver and Tidwell, LLP, to present the status update on the fiscal year 2019 internal audit plan and schedule. Mr. Graves delivered the report, noting that the fieldwork for the State Reporting Internal Audit and State Auditor’s Office Performance Measures Follow Up Procedures began October 22, 2018.

Responding to an Oversight Committee member’s question, Mr. Graves clarified that the internal audit includes an evaluation of risks and internal controls in place related to CPRIT’s State Reporting practices. Activities considered in the evaluation include Annual Reports, Research/Analytical Supporting, the Texas Cancer Plan, Public Information Act Requests, and Ad Hoc Reporting.

He went on to explain that the Budget and Planning Internal Audit would begin next week, and that they plan the remaining follow-up procedures for February 2019. At Presiding Officer Montgomery’s direction, he explained the chart on 11-4.

Amendments to 25 T.A.C. Chapters 703 – Agenda Item 16 – Tab 12

Presiding Officer Montgomery recognized Ms. Cameron Eckel, staff attorney, to present the final orders and new proposed rule changes to Texas Administrative Code Chapter 703. Ms. Eckel reported that the Board Governance subcommittee recommended the adoption of the proposed administrative rule changes to Chapter 703 as originally considered at the August meeting. She stated that CPRIT will submit the approved amendments to the Secretary of State and the changes will be effective 20 days later. Ms. Eckel also reported that the Board Governance subcommittee recommended publication of new proposed rule amendments to Chapter 703 in the *Texas Register* for public comment. These rule amendments will be brought back to the Oversight Committee for final adoption at the meeting in February.

MOTION:

On a motion by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the final orders adopting rules changes to the Texas Administrative Code Chapters 703.

MOTION:

On a motion by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the publication of the proposed changes to the Texas Administrative Code Chapter 703 in the *Texas Register*.

Amendments to the Oversight Committee Bylaws– Agenda Item 17 – Tab 13

Presiding Officer Montgomery recognized Ms. Doyle to explain the proposed change to the Oversight Committee bylaws. Ms. Doyle reported that the proposed change will require the Oversight Committee members to received periodic training.

MOTION:

On a motion by Dr. Rice and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the change to the Oversight Committee bylaws section 3.15.

Chief Operating Officer Report – Agenda Item 18 – Tab 14

Presiding Officer Montgomery recognized Heidi McConnell to present the Chief Operating Officer's Report. Ms. McConnell reported that grantees paid \$186,000 in revenue sharing. She also reviewed debt issuance and explained that \$1.5 billion debt had been issued over the life of the agency and Texas Public Finance Authority predicted \$2.9 billion in principal and \$1.6 billion in interest would be issued through 2049.

Dr. Rosenfeld inquired if interest rates affected bonds. Ms. McConnell responded that interest rates do affect bonds and directed members to percentage calculations by the Texas Public Finance Authority.

Subcommittee Business – Agenda Item 19 – Tab 14

Presiding Officer Montgomery announced that he appointed new Oversight Committee member Dr. Cummings to serve as a member of the Prevention and Audit Subcommittees.

MOTION:

On a motion by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve Dr. Cummings' appointments to the Prevention and Audit subcommittees.

**Compliance Investigation Pursuant to Health & Safety Code 102.2631 – Agenda Item 20
Consultation with General Counsel – Agenda Item 21**

Presiding Officer Montgomery announced that standing items 20 and 21 would not be taken up.

Future Meeting Dates and Agenda Items – Agenda Item 22


Presiding Officer Montgomery informed members that the next Oversight Committee meeting will occur on Thursday, February 21, 2019 at the Texas Higher Education Coordinating Board.

Adjourn – Agenda Item 23


MOTION:

There being no further business, the Oversight Committee unanimously approved a motion to adjourn made by Dr. Rosenfeld and seconded Dr. Patel.

Meeting adjourned at 12:23 p.m.

A handwritten signature in black ink, consisting of several loops and a long horizontal stroke extending to the right.

Signature

A handwritten date in black ink, appearing to be "2/22".

Date

